|
New
implanted stent system
evaluates blood
flow
from
the Catalyst, April 1, 2011
MUSC
became one of the first
centers nationwide to
implant the MISAGO
Self-expanding Stent System,
as part of a clinical trial
evaluating the
system's ability to improve
blood flow to the lower
extremities for
patients suffering from
peripheral artery disease
(PAD).
The
clinical trial, called the
Occlusive/Stenotic
Peripheral artery
REvascularization Study
(OSPREY) in the U.S., will
evaluate the safety
and efficacy of the stent
system for use in the
superficial femoral
artery (SFA), the main blood
vessel that supplies blood
to the legs and
feet.
For
patients suffering from PAD,
the MISAGO stent system
offers a way to
improve blood flow to
clogged vessels that supply
blood to the lower
extremities. An estimated
eight million Americans
suffer from PAD, with
the most common symptoms
including cramping, pain or
tiredness of the
leg or hip muscles while
walking or climbing stairs.
Most cases of PAD
can be managed with
lifestyle changes and
medical therapy; however,
left untreated, this
condition can lead to
gangrene and amputation of
the affected limb.
Marcelo
Guimaraes, M.D., MUSC
assistant professor of
vascular &
interventional radiology and
principal investigator on
the study, said
MUSC is pleased to be a part
of this landmark trial.
"This
is a unique and exciting
opportunity to be a part of
the first
international initiative to
streamline the regulatory
process to
facilitate future medical
device approvals between
countries. I believe
this is also important,
because it will increase the
population
awareness of peripheral
arterial disease, its
symptoms, how to prevent
it and how to manage it
adequately."
Click
here
to read entire article.
|